Cambrex invests $24 million in new HPAPI manufacturing capacity at its Charles City, Iowa facility

Project also includes reconfigure the existing small-scale manufacturing area providing a single high-containment building to support early-stage development and manufacturing.

The 4,500 sq. ft. production area will operate to an occupational exposure limit (OEL) down to 0.1µg/m3 and have a total reactor capacity of 2,200 gallons, which will be made up from a range of 200, 500 and 1,000 gallon glass and Hastelloy vessels to manufacture batches from 50 to 300kg. The project will also reconfigure the existing small-scale manufacturing area providing a single high containment building to support early-stage development and manufacturing, providing flexibility across a broad range of scale. Construction and installation of all new equipment is expected to be completed by Q1 2019. “This expansion is in line with Cambrex’s commitment to ongoing investment in small molecule manufacturing, as well as responding to the rising number of APIs that require specialized handling due to potency and toxicity,” commented Shawn Cavanagh, COO of Cambrex. He added, “Cambrex has built a strong reputation in the clinical-scale supply of potent, and extremely potent molecules, and the flexibility that this facility will give allows us to effectively handle projects throughout their development and commercial life-cycle.” This latest expansion is part of an ongoing strategic campaign to invest in small molecule API development and manufacturing across Cambrex’s global network of facilities, and follows the opening of a $50 million, 7,500 sq. ft. multi-purpose manufacturing facility at Charles City in 2016, which added a total of 70m3 of manufacturing capacity to the site.